Role of Plasmapheresis in Acute Yellow Phosphorus Poisoning

Authors
Dr Aparna Jayara and Dr Pratit Samdani

Introduction
There are three major forms of elemental Phosphorus present in environment – white, red, and black. Red phosphorus causes discoloration of white phosphorus leading to formation of yellow phosphorus. Yellow phosphorus is used in many industrial products like rodenticides, firework and fertilizers. Its easy availability makes it impossible to prevent and control the incidence of phosphorus poisoning. Fatal dose of yellow phosphorus is 1mg/kg.

In our case report we are presenting a case of 41 year old male who developed acute liver dysfunction due to yellow phosphorus poisoning and was well managed with plasmapheresis.

Case Report
A 41-year-old male presented with ingestion of rodenticide poison in the form of a 15gm of paste containing 3% phosphorous. On evaluation, patient was hemodynamically stable with sinus tachycardia of 120/min. There was no evidence of hepatic encephalopathy. His INR on admission was 1.61. Arterial blood gas (ABG) analysis was suggestive of compensated metabolic acidosis with serum bicarbonate of 11mEq/L. Later, on the same day patient developed hypotension and was started on vasopressor (i.e. noradrenaline infusion).

He was given full therapeutic dose of N-Acetyl Cysteine (NAC) i.e. 150mg/kg in 200 ml D5 over 1hour (as bolus), 50mg/kg in 500ml D5 over 4 hours, 100mg/kg in 1000ml D5 over 16 hours. Along with it, he was given Pantoprazole infusion, injection vitamin K and injection sodium bicarbonate infusion.

Abdominal sonography done on day 3, showed mildly thickened and oedematous gall bladder wall with pericholecystic fluid (image 1). Abdominal sonography shows mildly thickened and edematous GB wall with pericholecystic fluid
2D Echocardiography was done, in which his Left Ventricular Ejection Fraction was 20% with marked generalized Left Ventricular hypokinesia and severe LV diastolic dysfunction. On day 4, his INR further increased to 3.56, SGPT and SGOT increased to 1142 U/L and 713 U/L respectively. On day 5, his total leukocyte count (TLC) decreased to 1,500/µL and his platelet count decreased to 81000/µL. He was given 3 plasma exchange sessions on 5th, 6th and 7th day of his toxin ingestion. On 6th day, after 2 cycles of plasmapheresis, his INR reduced to 1.9. TLC improved to 2,060/µL, and SGPT and SGOT reduced to 711 and 1440 U/L respectively. His Noradrenaline infusion was completely tapered off on day 8, after 3rd cycle of plasma exchange. His 2D echo repeated on day 8 which showed his ejection fraction normalized to 45 to 50% with normal chamber dimensions. Patient was shifted to ward on day 10 of hospital admission. Patient’s Investigations on admission and on subsequent days are tabulated in chart (table 1).

### Table 1

<table>
<thead>
<tr>
<th></th>
<th>D1</th>
<th>D2</th>
<th>D3</th>
<th>D4</th>
<th>D5</th>
<th>D6</th>
<th>D7</th>
<th>D8</th>
<th>D9</th>
<th>D10</th>
</tr>
</thead>
<tbody>
<tr>
<td>HB (gm%)</td>
<td>14.4</td>
<td>14.8</td>
<td>14.2</td>
<td>13.5</td>
<td>14.4</td>
<td>14.4</td>
<td>13</td>
<td>12.1</td>
<td>10.3</td>
<td>10.5</td>
</tr>
<tr>
<td>WBC (/µL)</td>
<td>6580</td>
<td>7530</td>
<td>6850</td>
<td>2880</td>
<td>1590</td>
<td>2060</td>
<td>8500</td>
<td>9800</td>
<td>11310</td>
<td>13110</td>
</tr>
<tr>
<td>PLT (/µL)</td>
<td>3,17,000</td>
<td>2,70,000</td>
<td>2,00,000</td>
<td>1,37,000</td>
<td>81,000</td>
<td>70,000</td>
<td>83,000</td>
<td>1,14,000</td>
<td>1,39,000</td>
<td>1,95,000</td>
</tr>
<tr>
<td>INR</td>
<td>1.35</td>
<td>2.35</td>
<td>3.56</td>
<td>3.33</td>
<td>3.28</td>
<td>2.82</td>
<td>4.31</td>
<td>3.85</td>
<td>5.14</td>
<td></td>
</tr>
<tr>
<td>POTASSIUM (mmol/L)</td>
<td>4.86</td>
<td>3.72</td>
<td>2.5</td>
<td>2.67</td>
<td>3.33</td>
<td>3.28</td>
<td>2.82</td>
<td>4.31</td>
<td>3.85</td>
<td>5.14</td>
</tr>
<tr>
<td>SGOT (U/L)</td>
<td>45</td>
<td>88</td>
<td>78</td>
<td>1142</td>
<td>2892</td>
<td>1440</td>
<td>327</td>
<td>165</td>
<td>133</td>
<td>107</td>
</tr>
<tr>
<td>SGPT (U/L)</td>
<td>44</td>
<td>66</td>
<td>61</td>
<td>713</td>
<td>1443</td>
<td>711</td>
<td>315</td>
<td>237</td>
<td>205</td>
<td>189</td>
</tr>
<tr>
<td>BILIRUBIN (mg/dL)</td>
<td>0.30</td>
<td>0.43</td>
<td>0.46</td>
<td>1.02</td>
<td>2.97</td>
<td>3.28</td>
<td>4.41</td>
<td>5.05</td>
<td>4.97</td>
<td>3.10</td>
</tr>
<tr>
<td>LACTATE (mmol/L)</td>
<td>6.8</td>
<td>2.0</td>
<td>1.2</td>
<td>1.7</td>
<td>1.5</td>
<td>1.1</td>
<td>0.6</td>
<td>0.9</td>
<td>0.8</td>
<td></td>
</tr>
</tbody>
</table>

### Discussion

Yellow Phosphorus causes toxicity by an exothermic reaction which leads to free radical production and affects multiple organs. Fernandez and Canizares in a case series of 15 patients in 1995 and Nalabothuetal in 2015 reported that yellow phosphorus ingestion carries a high mortality. Usually during the first 48–72 h, only minimal gastrointestinal symptoms are manifested but subsequently acute liver failure ensues, progressing to multi-organ failure and death in extreme cases. In our patient also, presenting symptoms were typically GI symptoms i.e. abdominal pain and vomiting. On evaluation he had tachycardia (pulse of 120 beats/min), a respiratory rate of 20 counts/min, and a blood pressure of 112/72 mmHg in the supine position. Glasgow coma scale score was 15 with ABG showing compensated metabolic acidosis.

In Yellow Phosphorus poisoning, cardiac failure may ensue because of fluid and electrolyte loss (secondary to electrolyte abnormalities such as hypocalcemia and hyperkalemia) due to vomiting or diarrhoea or due to direct cardiac toxicity. In Our patient hypotension developed after admission and pump function of heart dropped to 20% with generalized LV hypokinesia. It was managed with IV fluids was vasopressors. There is no specific antidote for yellow phosphorus poisoning. Gastric lavage with potassium permanganate converts the phosphorus to relatively harmless oxides. Careful monitoring of liver and kidney function is required. Liver transplantation has been done in suitable candidates for acute hepatic failure. Studies have shown no clear benefit from N-acetyl cysteine, corticosteroids, or exchange transfusion. Our patient was given N-acetyl cysteine on the day of admission but his liver function and INR...
kept on deteriorating, a sharp increase being seen on the 4th day, so from the 5th day to the 7th day he was given 3 cycles of plasmapheresis and by the second cycle of plasmapheresis i.e. on the 6th day his laboratory investigations including INR started coming back to normal, and his general condition started improving. Plasmapheresis was given by replacing full plasma volume (calculated on the basis of body weight and hematocrit) with fresh frozen plasma.

A study by Varghese J et al.12, Matthew J et al.13 and Angraje S et al.14 also support therapeutic plasma exchange in management of yellow phosphorus poisoning with remarkable improvement in outcomes.

Conclusion
Yellow phosphorus poisoning is a big threat as suicide weapon because of its wide use in manufacture of multiple industrial products. Development of resistance of rodents to warfarin makes use of yellow phosphorus more prevalent. Though the ideal way to deal with this problem will be to discourage its use as an ingredient of rodenticide and to look for other alternatives. Clinicians should be aware of its toxicity and use of plasmapheresis in early stages should be encouraged in management of acute yellow phosphorus poisoning.

References
11. Marin GA, Montoya CA, Sierra JL, Senior JR. Evaluation of corticosteroid and

